Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

Kennedy, a longtime anti-vaccine activist who had criticized the panel of experts, said he would pick the committee's new members.

Africa is grappling with a worsening mpox crisis, with a critical shortfall of vaccine doses threatening to derail ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a statement on Tuesday, June 10, the Public Health Principal Secretary, Mary Muthoni, said the latest counties to be ...

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a ...